Evotec vs Ultragenyx Pharmaceutical
EVO and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EVO and RARE compare
Ultragenyx Pharmaceutical grew revenue faster over the last twelve months (15.8% versus −1.1% for Evotec).
Ultragenyx Pharmaceutical scores higher on the StockData Score (9 against 4 for Evotec), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EVO | RARE |
|---|---|---|
| Size and price | ||
| Market cap | – | $1.6B |
| Share price | $1.69 | $16.70 |
| Change, 1 year | −43.5% | −47.7% |
| Change, 5 years | −92.9% | −78.9% |
| Beta (5Y) | 1.26 | 1.08 |
| Employees | 4,553 | 1,371 |
| StockData Score | ||
| Total score | 4 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 2.3× |
| FCF yield | – | −26.8% |
| Growth | ||
| Revenue growth (TTM) | −1.1% | 15.8% (better) |
| Revenue growth, 5Y average | 9.5% | 19.9% (better) |
| Profitability | ||
| Gross margin | 14.5% | – |
| Operating margin | −7.1% (better) | −64.0% |
| Net margin | – | −71.8% |
| FCF margin | −10.4% (better) | −60.5% |
| Return on invested capital | −7.7% | – |
| Financial health | ||
| Debt / equity | 0.10 | – |
| Net debt / EBITDA | −7.79 | – |
| Current ratio | 2.07 (better) | 1.40 |
| Altman Z-score | – | −5.70 |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 1.8% | 108% |
| Held by insiders | 17.1% | 4.0% |
| Insider net buying, 12 months | – | −$3.8M |
| Short interest, % of float | – | 25.0% |
Go deeper
- EVO stock overview
- EVO income statement
- EVO valuation and score
- RARE stock overview
- RARE income statement
- RARE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.